"Global drug delivery technology market will reach $198.4 billion in 2017"

LONDON - Oct. 7, 2013 - PRLog -- The market for drug delivery technology (DDT) has expanded rapidly in recent years, with impressive sales growth and important trends. These technologies provide pharmaceutical (http://www.visiongain.com/Sector/8/Pharma) companies with novel strategies for the delivery of biologically active drug candidates. Developments in DDT offer valuable options for product line extensions. Furthermore, drug manufacturers continuously strive to develop drug delivery options that provide patient-friendly dosage forms. Consequently, drug delivery technology will continue to play an important role in developing next generation drugs, particularly in biologics and vaccines.

Dr Syed Ahmed, a senior healthcare industry analyst in visiongain says ‘’Drug delivery technology platforms are used by pharmaceutical companies for a number of reasons. These range from extension of product life cycle through to providing novel, innovative and convenient ways for delivering drugs to the patients.

‘‘Drug delivery systems are an enabling technology that can improve the bioavailability of drugs or add convenience and safety. Some molecules such as oligos and peptides have an intrinsic need for good delivery systems and novel technologies are playing a very important role there. Also, these technologies are essential for enhancing efficacy, reducing risk profile and increasing convenience and compliance. In addition, they are important for introducing products into newer markets such as paediatrics.’’

Visiongain forecasts that the overall market for drug delivery technologies will grow steadily to 2023. An increasing focus on biologics and other innovative treatments in a wide range of therapeutic areas will drive the sector.

Visiongain’s report gives revenue forecasts to 2023 at overall world market, submarket and national level. It forecasts world sales for the following submarkets:

Oral delivery
Inhaled delivery
Transdermal delivery
Ocular delivery
Nasal delivery
Implants for drug delivery.

The study discusses 3M, Catalent, Alkermes, Generex Biotechnology, pSivida, PharmaJet and many other technology providers, letting you assess outlooks for the industry and market.

The study includes researching trends and forecasting revenues in leading national markets. Countries analysed are the US, Japan, Germany, France, the UK, Spain, Italy, India and China. The analysis also discusses opportunities and developments – technological and commercial.

Drug Delivery Technologies: Commercial Prospects 2013-2023 adds to visiongain’s range of analytical reports on industries and markets in healthcare.

For further information concerning the visiongain’s report Drug Delivery Technologies: Commercial Prospects 2013-2023 please visit

http://www.visiongain.com/Report/1042/Drug-Delivery-Technologies-Commercial-Prospects-2013-2023